1. Somatic mutations of cell-free circulating DNA detected by targeted next-generation sequencing and digital droplet PCR in classical Hodgkin lymphoma
- Author
-
Marie Cornic, Catherine Maingonnat, Lucile Bessi, Pascaline Etancelin, Pierre-Julien Viailly, Philippe Bertrand, Ludivine Beaussire, Philippe Ruminy, Aspasia Stamatoullas, Vincent Camus, NasrinSarafan Vasseur, Elodie Bohers, Jean-Michel Picquenot, Hervé Tilly, Fabrice Jardin, Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), service d'anatomo-pathologie, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), and Service d'hématologie
- Subjects
Cancer Research ,Somatic cell ,[SDV]Life Sciences [q-bio] ,macromolecular substances ,Cell free ,Biology ,Polymerase Chain Reaction ,DNA sequencing ,Circulating Tumor DNA ,03 medical and health sciences ,0302 clinical medicine ,Refractory ,immune system diseases ,hemic and lymphatic diseases ,polycyclic compounds ,Classical Hodgkin lymphoma ,Biomarkers, Tumor ,Humans ,Genetic Predisposition to Disease ,Digital droplet pcr ,Genetic Association Studies ,ComputingMilieux_MISCELLANEOUS ,food and beverages ,High-Throughput Nucleotide Sequencing ,Hematology ,DNA, Neoplasm ,Hodgkin Disease ,3. Good health ,Oncology ,030220 oncology & carcinogenesis ,Mutation ,Cancer research ,Circulating DNA ,030215 immunology - Abstract
Classical Hodgkin lymphoma (cHL) accounts for 30% of all lymphomas [1]. Currently, 20–25% of cHL cases relapse or are refractory after first-line standard treatments, leading to the need to better ...
- Published
- 2018
- Full Text
- View/download PDF